Special Offer Ends Soon!

“Underground” System Tracks 40% of Daily Wall St. Money

Millionaire Trader, Taylor Conway, creates Bloomberg scanner to track “Dark Pool” activity, opening the door for huge potential returns.

Learn how to position yourself for profit, before the markets move!

On the watch: Cidara Therapeutics Inc. (CDTX)

Kyle DennisKyle Dennis ·

The set-up: Cidara Therapeutics (CDTX) develops antibiotic drugs with a focus on treatment of serious fungal infections. It’s due to release results on a Phase 2 trial of echinocandin (CD101) in candidemia, with results expected in the fourth quarter. The stock value was cut in half in February, dropping from $11.70 to below $6, after disappointing Phase 2 trial data on a topical version of the same drug.

Why I like it: I like the company, the management team and the catalyst. I like the chances of them having positive data in Q4. This formulation is being delivered intravenously, and IV delivery of antibiotics usually is much more effective, and safer as well. I like that they’re an antibiotic company, because those tend to be a bit less risky. I also like the management team; Jeffrey Stein, Cidara’s CEO, used to run a company called Trius Therapeutics, which developed an antibiotic called tedizolid, got it through Phase 3 trials and was acquired by Cubist Pharmaceuticals, Inc. in 2013 for a nice premium.

How I’m playing it: I’ve added CDTX to my watch list, looking to buy it on dips. I think it’s a good buy between $6 and $6.50, with the potential to have a nice catalyst run up to $8; if they report positive data – though I typically sell stocks before the catalyst event occurs — CDTX could go back up to $10 a share, and maybe all the way up to $12.

Listen to Kyle Dennis discuss Cidara in the Raging Bull podcast


Kyle Dennis runs Kyle Dennis’ Biotech Breakouts (biotechbreakouts.com). He is an event-based trader, who prefers low-priced and small-cap biotech stocks.  He currently has no shares, options or open orders in CDTX; he last owned the stock on April 26, when he played it as a day trade.

Trending Now

Bull or Bear Market….It Doesn’t Matter

Kyle Dennis’ new, 5 min strategy is poised to double account sizes weekly! “I got out of GE trade at 379% $0.16-$0.77, thanks Kyle!” Said client Lance P. Check out the free training that started it all. (View Free Training)

SuperNova Service Leading Clients to 5-Figure Profits Consistently

“BOOM!!! Booked another $13,985 in profits on my long position $VMNGF. Great report came out premarket. Thanks Jeff at SuperNova for teaching me to make $$$ in the market.” Said Todd V. Jeff Williams is helping transform small accounts daily. Don’t miss his free walkthrough. (Watch Now)

Jeff Bishop, RagingBull.com Co-Founder, “Trading My Strategy Takes A Few Minutes a Day!” 

“Jeff, I have to say I was a little gun shy, but I bought the lifetime service (to Bullseye Trades) Friday night. First trade with your service…in LULU, 205 Calls at $4.70. (I) was going to be away from all internet connections for the next 3 days. It hit my sell price at $6.25 ;)” said James W.    (Read More)

Be a Better Stock Trader, Starting Today

Get the expert insights, tips and strategies you need to optimize your trading skills and profiles